Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)Niven Mehra, Johann S. de Bono, Mario A. Eisenberger et al.|European Urology|2018Cited by 110
Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate CancerAdam Sharp, Johann S. de Bono, Jon Welti et al.|European Urology|2019Cited by 83
Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNASemini Sumanasuriya, Johann S. de Bono, George Seed et al.|European Urology|2021Cited by 65
First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic CancerSarah P. Blagden, Udai Banerji, Aurelius Olmin et al.|Clinical Cancer Research|2014Cited by 47
A pharmacokinetic (PK) pharmacodynamic (PD) driven first-in-human study of the oral class I PI3K inhibitor CH5132799, in patients with advanced solid tumors.Aurelius Omlin, Sarah P. Blagden, James Spicer et al.|Journal of Clinical Oncology|2012Cited by 5